Other
CN
EU
USA
Description: Edoxaban (also known as DU-176b) is a potent, selective, orally bioavailable factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is used as an anticoagulant drug. Edoxaban acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.
References: J Thromb Haemost. 2008 Sep;6(9):1542-9.
Related CAS #: 480448-29-1 (HCl) 1229194-11-9 (tosylate hydrate) 480449-71-6 (tosylate) 480449-70-5 (free base)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity: In human plasma, Edoxaban doubles prothrombin time and activates partial thromboplastin time at 0.256 and 0.508 μM, respectively.
Cell Assay: Edoxaban (DU-176b) inhibited FXa with Ki values of 0.561 nM for free FXa, 2.98 nM for prothrombinase, and exhibited >10 000-fold selectivity for FXa. DU-176b doubled prothrombin time and activated partial thromboplastin time in human plasma. DU-176b did not impair platelet aggregation by ADP, collagen or U46619 .
J Thromb Haemost. 2008 Sep;6(9):1542-9.
Purity ≥98%
COA
MSDS
NMR